Quality of Life and Pain With Infiltration or Suprascapular Nerve Block in Glenohumeral Arthirtis

Study Overview
=================
Brief Summary
-----------------
Efficacy in pain and health related quality of life of suprascapular nerve block ultrasound guided and glenohumeral infiltration in glenohumeral arthritis

Detailed Description
-----------------
To describe the efficacy in pain management and health related quality of life of suprascapular nerve block ultrasound guided and glenohumeral infiltration in patients with glenohumeral arthritis

Official Title
-----------------
Health Related Quality of Life and Pain Managment Using Infiltration or Suprascapular Nerve Block Ultrasound Guided in Patients With Glenohumeral Arthirtis

Conditions
-----------------
Shoulder Arthritis

Intervention / Treatment
-----------------
* Drug: Methylprednisolone Acetate
* Drug: Lidocaine 2% Injectable Solution
* Drug: Ropivacaine HCl Inj 7.5 MG/ML


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IMSS affiliated Glenohumeral arthritis diagnosed Exclusion Criteria: Previusly treatment for the same disease No follow up Dead

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Shoulder infiltration<br>Shoulder infiltration using 2 ml of Lidocaine 2% Injectable Solution and methylprednisolone acetate 40 mg | Drug: Methylprednisolone Acetate<br>* depo-medrol 40 mg<br>* Other names: depo-medrol 40 mg;Drug: Lidocaine 2% Injectable Solution<br>* 2ml of 2% lidocaine<br>* Other names: xilocaine;|
| Experimental: Suprascapular nerve block<br>Suprascapular nerve block ultrasound guided using 25 mg of Ropivacaine HCl Inj 7.5 MG/ML and methylprednisolone acetate 40 mg | Drug: Methylprednisolone Acetate<br>* depo-medrol 40 mg<br>* Other names: depo-medrol 40 mg;Drug: Ropivacaine HCl Inj 7.5 MG/ML<br>* 25 mg<br>* Other names: Ropivacaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain before | visual analogue scale | VAS before intervention | 
| Pain 2 months after | Visual analogue scale 2 months after procedure | VAS 2 months after | 
| Pain 6 months after | Visual analogue scale 6 months after procedure | VAS 6 months after | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life before procedure | SF12v2 Health related quality of life before procedure | SF12v2 before procedure | 
| Quality of life 2 months after procedure | SF12v2 Health related quality of life 2 months after | SF12v2 2 months after | 
| Quality of life 6 months after procedure | SF12v2 Health related quality of life 6 months after | SF12v2 6 months after |